VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened

Vertex Pharmaceuticals Incorporated (VRTX) reported adjusted earnings of $4.06 per share for the first quarter of 2025, missing the Zacks Consensus Estimate of$4.22. Earnings declined 14.7% on a year-over-year basis.The company reported total revenues of $2.77 billion for the first quarter, which missed the Zacks Consensus Estimate of$2.82 billion. Total revenues rose 3% year over year, primarily driven by higher sales of Trikafta/Kaftrio (marketed as Kaftrio in Europe). (Find the latest EPS estimates and ...